Study of SA+X in the Treatment of Newly Diagnosed AML

NCT07548710 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

205

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Anthracycline
DRUG: Ivosidenib
DRUG: Gilteritinib
DRUG: Sonrotoclax
DRUG: Azacitidine (AZA)

Sponsor

Ruijin Hospital